Asset profile
NH102
Small molecule
Evidence outlook · lead readout
NCT06842992 · Major Depressive Disorder (MDD)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06842992: The study randomized 243 participants and used quadruple masking with both placebo and an active duloxetine comparator. Its primary clinical endpoint was change in HAM-D17 score at six weeks, but results are not posted, so whether the endpoint was met or missed is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.